Research and Markets: LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists - Pipeline Insights, 2015

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/z45nhd/lag3) has announced the addition of the "LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists -Pipeline Insights, 2015" report to their offering.

LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists- Pipeline Insights, 2015 Report covers the LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. The Report also provides LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists related therapeutic assessments by molecule type, route of administration, monotherapy and combination products. The Report also highlights the discontinued and inactive projects in pipeline for LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists.

Key Topics Covered:

1. LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Overview

2. LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Disease Associated

3. LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Pipeline Therapeutics

4. LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Therapeutics under Development by Companies

5. LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Late Stage Products (Filed and Phase III)

- Comparative Analysis

6. LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Mid Clinical Stage Products (Phase II)

- Comparative Analysis

7. LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Early Clinical Stage Products (Phase I and IND Filed)

- Comparative Analysis

8. LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Discovery and Pre-Clinical Stage Products

9. LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists - Therapeutics Assessment

10. LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists - Discontinued Products

11. LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists - Dormant Products

For more information visit http://www.researchandmarkets.com/research/z45nhd/lag3

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices, Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices, Pharmaceuticals